ISSN 2149-2263 | E-ISSN 2149-2271
pdf
Volume : 25 Issue : 9 Year : 2021
Quick Search



Role of endocardial septal ablation in the treatment of hypertrophic obstructive cardiomyopathy [Anatol J Cardiol]
Anatol J Cardiol. 2016; 16(9): 707-712 | DOI: 10.14744/AnatolJCardiol.2016.7100

Role of endocardial septal ablation in the treatment of hypertrophic obstructive cardiomyopathy

Tolga Aksu1, Tümer Erdem Güler1, Kıvanç Yalın2, Şükriye Ebru Gölcük2, Kazım Serhan Özcan1
1Department of Cardiology, Kocaeli Derince Education and Research Hospital; Kocaeli-Turkey
2Department of Cardiology, Bayrampaşa Kolan Hospital; İstanbul-Turkey

Septal reduction therapy is accepted as a first therapeutic option for symptomatic drug-resistant hypertrophic obstructive cardiomyopathy (HOCM). Although, surgical septal myectomy is the gold standard method, alcohol septal ablation is a well-studied alternative approach in the patients with suitable anatomy. Endocardial septal ablation (ESA) therapy was relatively new defined modality and outcomes of the procedure were not clearly elucidated yet. We aimed to review the clinical aspects of ESA procedure and provide some historical background. (Anatol J Cardiol 2016; 16: 707-12)

Keywords: Ablation, hypertrophic obstructive cardiomyopathy, septal myectomy, alcohol septal ablation, radiofrequency

Tolga Aksu, Tümer Erdem Güler, Kıvanç Yalın, Şükriye Ebru Gölcük, Kazım Serhan Özcan. Role of endocardial septal ablation in the treatment of hypertrophic obstructive cardiomyopathy. Anatol J Cardiol. 2016; 16(9): 707-712

Corresponding Author: Tolga Aksu, Türkiye